After the Bhartiya Janata Party s decisive victories in Chattisgarh, Rajasthan, and Madhya Pradesh last Sunday, the market witnessed a robust rally, which briefly paused mid-week. However, as the week concluded, buying momentum resumed, propelling benchmark indices to fresh highs. This resurgence was attributed to positive global cues and the Reserve Bank of India s (RBI) optimistic revision of the FY23-24 GDP forecast to 7%, up from the earlier 6.5%, in its monetary policy announcement.
Zydus Receives Final Approval From The USFDA For Methylene Blue Injection freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Zydus receives Final Approval from the USFDA for Methylene Blue Injection equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the pharma company said.
On Wednesday, 1930 stocks advanced, 1824 declined and 141 remained unchanged, with an advance decline ratio of 1.05 on the Bombay Stock Exchange (BSE), indicating positive closing of stocks in broader markets.